Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?
Here is how AnaptysBio, Inc. (ANAB) and Electromed, Inc. (ELMD) have performed compared to their sector so far this year.
Zacks Investment Research5/21/2026Positive
ANAB
AnaptysBio IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.95B
P/E Ratio
—
EPS
$-1.02
Beta
0.38
52W High
$72.36
52W Low
$11.40
50-Day MA
$60.49
200-Day MA
$38.72
Dividend Yield
—
Profit Margin
-11.50%
Forward P/E
—
PEG Ratio
0.00
About AnaptysBio Inc
AnaptysBio, Inc., a clinical-stage biotechnology company, is dedicated to developing therapeutic product candidates for inflammation and immuno-oncology indications. The company is headquartered in San Diego, California.
Fundamentals
| Revenue (TTM) | $232.39M |
| Gross Profit (TTM) | $103.61M |
| EBITDA | $41.34M |
| Operating Margin | -135.50% |
| Return on Equity | -114.50% |
| Return on Assets | 6.78% |
| Revenue/Share (TTM) | $8.22 |
| Book Value | $0.44 |
| Price-to-Book | 147.31 |
| Price-to-Sales (TTM) | 8.40 |
| EV/Revenue | 6.91 |
| EV/EBITDA | 27.44 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -8.00% |
| Shares Outstanding | $29.61M |
| Float | $19.67M |
| % Insiders | 5.68% |
| % Institutions | 102.37% |
Historical Volatility
HV 10-Day
63.79%
HV 20-Day
54.28%
HV 30-Day
52.08%
HV 60-Day
67.01%
HV Rank
25.4%
Volatility is currently expanding
Analyst Ratings
Consensus ($87.09 target)
3
Strong Buy8
BuyLatest News
Wall Street Analysts See a 38.75% Upside in AnaptysBio (ANAB): Can the Stock Really Move This High?
The consensus price target hints at a 38.8% upside potential for AnaptysBio (ANAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Zacks Investment Research5/19/2026Positive
AnaptysBio (ANAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
After losing some value lately, a hammer chart pattern has been formed for AnaptysBio (ANAB), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Zacks Investment Research5/14/2026Positive
Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today reported financial results for the first quarter ended March 31, 2026, and provided a business update.
GlobeNewsWire5/12/2026Neutral
Anaptys Appoints Chris Murphy as Chief Financial Officer and Owen Hughes to Board of Directors
SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced the appointment of Christopher Murphy as Chief Financial Officer and Owen Hughes as a member of its Board of Directors.
GlobeNewsWire5/11/2026Neutral
AnaptysBio, Inc. (ANAB) is a Great Momentum Stock: Should You Buy?
Does AnaptysBio, Inc. (ANAB) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks Investment Research5/6/2026Positive
Are Medical Stocks Lagging AnaptysBio (ANAB) This Year?
Here is how AnaptysBio, Inc. (ANAB) and Coherus Oncology (CHRS) have performed compared to their sector so far this year.
Zacks Investment Research5/5/2026Negative
Anaptys to Participate at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that Daniel Faga, president and chief executive officer of Anaptys, is scheduled to participate in a fireside chat at the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference on Wednesday, May 6, 2026. The fireside chat is scheduled to begin at 1:30pm ET.
GlobeNewsWire5/4/2026Neutral
Arcus Biosciences, Inc. (RCUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Arcus Biosciences (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research4/28/2026Negative
AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
AnaptysBio (ANAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research4/27/2026Negative
More HEALTHCARE Stocks
Data last updated: 7/9/2026